Abstract:Abstract Individuals with severe atopic dermatitis (AD) may present with very high serum IgE levels (> 10 000 IU mL−1). Signal transducer and activator of transcription 3 hyper-IgE syndrome (STAT3-HIES), a rare immunosuppressive disorder, shares pathogenic similarities with AD, involving dysregulation in the STAT3 signalling pathway and clinical, genetic and serological features similar to AD. Despite these parallels, patients with AD with very high IgE levels are not routinely tested for genetic overlap with STAT3-HIES. This might be relevant in therapeutic intervention. We reviewed the literature to identify individuals with possible overlap of both conditions to help identify a novel mixed phenotype (AD/STAT3-HIES). Intervention with Janus kinase (JAK) inhibitors in this subgroup might be beneficial given their shared dysregulation in STAT3 signalling pathways. This review investigates the identification of the AD/STAT3-HIES phenotype and its response to Janus kinase (JAK) inhibitors. A literature review was undertaken on PubMed, Scopus, Ovid and Google Scholar. Search terms included ‘atopic dermatitis’, ‘hyper-IgE syndrome’, ‘HIES’, ‘Job syndrome’, ‘STAT3’, ‘JAK/STAT pathway’ and ‘Janus kinase inhibitors’. Inclusion criteria were studies published in English between January 2005 and December 2023 relevant to the clinical features, treatment, pathogenesis and genetics of AD or STAT3-HIES. Out of 152 studies identified during the search, 29 met the inclusion criteria. The Table outlines the features of AD, STAT3-HIES and areas of overlap (AD/STAT3-HIES). Clinically, AD and STAT3-HIES share characteristics including eczematous lesions and staphylococcal skin infections. STAT3-HIES is distinguished from AD by the presence of immunoparesis and extracutaneous manifestations. Both diseases commonly exhibit elevated IgE levels. In severe AD, studies reported IgE levels ranging from 356 to 2379 IU mL−1, while patients with STAT3-HIES demonstrated levels between 1000 and 46 850 IU mL−1. Genetically, both diseases are associated with the STAT3 and IL6 genes. JAK inhibitors proved effective in treating AD in multiple studies. To date, only one ex vivo study suggested a potential treatment utility of JAK inhibitors in dominant negative STAT3 mutation. We postulate that patients with AD with elevated IgE levels beyond the typical range may benefit from further genotyping (STAT3 and IL6 gene mutations) to identify the AD/STAT3-HIES phenotype. Future clinical trials could assess the potential benefits of targeted intervention with JAK inhibitors in this subgroup and/or in patients with AD with very high serum IgE.ADAD/STAT3-HIESSTAT3-HIESClinicalPruritic eczematous lesionsPruritic eczematous lesionsPruritic eczematous lesionsStaphylococcal skin infectionsStaphylococcal skin infectionsStaphylococcal skin infectionsCold staphylococcal abscessRecurrent pneumoniaSkeletal and dental abnormalitiesConnective tissue abnormalitiesSerologyElevated IgEElevated IgEElevated IgEGenetic associationsSTAT3STAT3STAT3IL6RIL6RIL6RFLGIL6STIL2/IL21ZNF341IL7RTYK2IL15RA/IL2RAImmunologicalElevated interleukin-4Elevated interleukin-4Elevated interleukin-4Elevated interleukin-13Elevated interleukin-13Elevated interleukin-13

Identifying potentially undiagnosed individuals with hyper-IgE syndrome using a scoring system

Phenotypes of 126 Moroccan HIES patients according to NIH Score

Challenges in diagnosing and managing hyper-IgE syndrome in a resource-limited setting: a case report

Reduced expression of chemoattractant receptors by polymorphonuclear leukocytes in Hyper IgE Syndrome patients

Validating Inborn Error of Immunity Prevalence and Risk with Nationally-Representative EHR Data

Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review

PA03 Should patients with atopic dermatitis be screened for genes associated with hyper-IgE syndrome?

Expanded targeted preconception screening panel in Israel: findings and insights

High rates of mood disorders in patients with chronic idiopathic eosinopenia

Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome

Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome

Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome

Electronic health record signatures identify undiagnosed patients with common variable immunodeficiency disease

Inborn errors of immunity in Canadian First Nations and Nunavut Inuit Children: the tip of the iceberg

Enrichment of Immune Dysregulation Disorders in Adult Patients with Human Inborn Errors of Immunity

Immunological status in patients with neuroendocrine cell hyperplasia of infancy. CRC chILD-EU

A unified metric of human immune health

Genetic causes of primary immunodeficiency in the Jordanian population

Harnessing artificial intelligence to infer novel spatial biomarkers for the diagnosis of eosinophilic esophagitis

Increase Incidence and Prevalence of Eosinophilic Gastrointestinal Disorders in Israel During the Last Decade

Next-generation reference interval for total IgE in the United States: A retrospective real-world analysis